Status: Recruiting
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.
Participants needed: 228
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: BiocadUpdated: Aug 13, 2025Locations: 2
Eligibility criteria
The patient signed a written ICF for participation in the study. [+12]
Any other diagnosed forms of anemia, except for anemia of renal disease, includi... [+25]